P-007
PCP (Phencyclidin) -Lösung
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Synonym(e):
Phencyclidine
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empirische Formel (Hill-System):
C17H25N
CAS-Nummer:
Molekulargewicht:
243.39
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24
Empfohlene Produkte
Qualität
certified reference material
Form
liquid
Leistungsmerkmale
Snap-N-Spike®/Snap-N-Shoot®
Verpackung
ampule of 1 mL
Hersteller/Markenname
Cerilliant®
drug control
Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIA (Portugal)
Konzentration
1.0 mg/mL in methanol
Methode(n)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
Anwendung(en)
forensics and toxicology
Format
single component solution
Lagertemp.
2-8°C
InChI
1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2
InChIKey
JTJMJGYZQZDUJJ-UHFFFAOYSA-N
Allgemeine Beschreibung
Phencyclidine, commonly known as PCP, is a recreational drug with hallucinogenic and neurotoxic effects. With street names such as "angel dust" or "wet", PCP comes in either powder or liquid forms. The illicit drug is typically sprayed onto leafy material such as cannabis and then smoked. This certified solution standard is suitable for use as starting material in calibrators and controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing.
Phencyclidine, commonly known as PCP, is a recreational drug with hallucinogenic and neurotoxic effects. With street names such as "angel dust" or "wet", PCP comes in either powder or liquid forms. The illicit drug is typically sprayed onto leafy material such as cannabis and then smoked. This certified solution standard is suitable for use as starting material in calibrators and controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing.
Anwendung
- A Collaborative Platform for Novel Compound Identification - Characterization of Designer Phencyclidines (PCPs) POXP, PTHP, and P2AP: This research highlights a collaborative platform for the identification and characterization of novel designer PCPs, emphasizing their potential as analytical standards and sigma receptor agonists. The study provides valuable insights for scientists involved in receptor binding studies and the development of dissociative anesthetics for research (Sisco, Urbas, 2023).
- Long-term adaptation of prefrontal circuits in a mouse model of NMDAR hypofunction: Investigating the long-term effects of NMDAR hypofunction in mice, this study uses PCP to elucidate mechanisms of schizophrenia, showcasing its application as a NMDA receptor antagonist in neuropharmacological studies. The findings are crucial for advancing knowledge on neurotransmitter research and mental health disorders (Ponserre et al., 2024).
- 3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an (18)F-FDG PET/CT Case Report: This review and case report discuss the psychiatric implications of 3-Methoxy-Phencyclidine, a derivative of PCP, providing insights into its effects on human cognition and behavior. Such studies are essential for developing high-purity PCP liquids for sigma receptor assays and understanding its role as a non-competitive NMDA antagonist (Pepe et al., 2024).
- Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens: This review explores the dermatological reactions associated with psychedelic drugs, including PCP. It underscores the importance of understanding the biochemical pathways affected by PCP, reinforcing its utility as a research chemical in pharmaceutical applications (Rahman et al., 2024).
- Novel α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) potentiator LT-102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia: This research explores the potential therapeutic uses of AMPAR potentiators, highlighting PCP′s role in enhancing understanding of glutamatergic dysfunction in schizophrenia. It showcases PCP′s utility in developing treatments that modulate neurotransmitter systems, valuable for neuropharmacology research (Qi et al., 2024).
Rechtliche Hinweise
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Signalwort
Danger
H-Sätze
Gefahreneinstufungen
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Zielorgane
Eyes,Central nervous system
Lagerklassenschlüssel
3 - Flammable liquids
WGK
WGK 2
Flammpunkt (°F)
49.5 °F - closed cup
Flammpunkt (°C)
9.7 °C - closed cup
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Masakuni Horiguchi et al.
Behavioural brain research, 238, 36-43 (2012-09-29)
Development of dopamine (DA) D(1) receptor agonists is a priority to improve cognitive impairment in schizophrenia (CIS). This study examined the dose-response relationship of the selective D(1) agonist, SKF38393 (0.5-40 mg/kg), to reverse the deficit in novel object recognition (NOR)
Jens Köhler et al.
Journal of medicinal chemistry, 55(20), 8953-8957 (2012-09-28)
We synthesized and investigated the NMDA and σ₁ receptor affinity of enantiomerically pure 2-(2-phenyl-1,3-dioxan-4-yl)ethanamines 17-26. The primary amines (R,R)-18-20 with an axially oriented phenyl moiety in position 2 interacted with high enantioselectivity (eudismic ratios 70-130) and high affinity (K(i)((R,R)-19) =
Daniel C Javitt et al.
Schizophrenia bulletin, 38(5), 958-966 (2012-09-19)
Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews
Ross Zimnisky et al.
Psychopharmacology, 226(1), 91-100 (2012-10-20)
A major challenge in the pharmacological treatment of psychotic disorders is the effective management of the associated cognitive dysfunctions. Novel concepts emphasize a potential benefit of partial agonists acting upon dopamine D(2)-like receptors in ameliorating these cognitive deficits, and pre-clinical
Ramin Hajikhani et al.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 21(3), 307-312 (2012-12-12)
The study attempted to investigate the anti-anxiety activities of Phencyclidine (1-(1-phenylcyclohexyl) piperidine, PCP, I) and some of its derivatives (M, F, L, B, S, P) with the elevated-plus maze (EPM) Test. Phencyclidine and its derivatives (M, F, L, B, S
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.